vs
Side-by-side financial comparison of Entrada Therapeutics, Inc. (TRDA) and UNITED SECURITY BANCSHARES (UBFO). Click either name above to swap in a different company.
Entrada Therapeutics, Inc. is the larger business by last-quarter revenue ($20.6M vs $13.5M, roughly 1.5× UNITED SECURITY BANCSHARES). UNITED SECURITY BANCSHARES runs the higher net margin — 25.2% vs -84.4%, a 109.6% gap on every dollar of revenue. On growth, UNITED SECURITY BANCSHARES posted the faster year-over-year revenue change (13.6% vs -65.2%). UNITED SECURITY BANCSHARES produced more free cash flow last quarter ($19.8M vs $-39.7M). Over the past eight quarters, Entrada Therapeutics, Inc.'s revenue compounded faster (6.4% CAGR vs 3.0%).
Entrada Therapeutics is a clinical-stage biotechnology firm developing transformative intracellular therapies for serious rare diseases and high-unmet-need disorders. Its pipeline covers neuromuscular, metabolic, and central nervous system segments, serving global patients via healthcare partnerships.
United Security Bancshares is a bank holding company headquartered in Fresno, California. It operates 11 branches.
TRDA vs UBFO — Head-to-Head
Income Statement — Q1 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $20.6M | $13.5M |
| Net Profit | $-17.3M | $3.4M |
| Gross Margin | — | — |
| Operating Margin | -106.0% | 31.5% |
| Net Margin | -84.4% | 25.2% |
| Revenue YoY | -65.2% | 13.6% |
| Net Profit YoY | -173.8% | 36.8% |
| EPS (diluted) | $-0.42 | $0.18 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $13.5M | ||
| Q3 25 | — | $14.0M | ||
| Q2 25 | — | $12.6M | ||
| Q1 25 | $20.6M | $13.7M | ||
| Q4 24 | $37.4M | $11.9M | ||
| Q3 24 | $19.6M | $13.8M | ||
| Q2 24 | $94.7M | $13.0M | ||
| Q1 24 | $59.1M | $12.8M |
| Q4 25 | — | $3.4M | ||
| Q3 25 | — | $4.0M | ||
| Q2 25 | — | $2.2M | ||
| Q1 25 | $-17.3M | $2.7M | ||
| Q4 24 | $1.1M | $2.5M | ||
| Q3 24 | $-14.0M | $3.8M | ||
| Q2 24 | $55.0M | $4.3M | ||
| Q1 24 | $23.5M | $4.2M |
| Q4 25 | — | 31.5% | ||
| Q3 25 | — | 40.3% | ||
| Q2 25 | — | 24.0% | ||
| Q1 25 | -106.0% | 27.5% | ||
| Q4 24 | -15.7% | 27.5% | ||
| Q3 24 | -110.7% | 37.1% | ||
| Q2 24 | 56.4% | 46.4% | ||
| Q1 24 | 35.7% | 45.9% |
| Q4 25 | — | 25.2% | ||
| Q3 25 | — | 28.7% | ||
| Q2 25 | — | 17.2% | ||
| Q1 25 | -84.4% | 19.6% | ||
| Q4 24 | 3.0% | 20.9% | ||
| Q3 24 | -71.7% | 27.7% | ||
| Q2 24 | 58.1% | 33.0% | ||
| Q1 24 | 39.7% | 32.6% |
| Q4 25 | — | $0.18 | ||
| Q3 25 | — | $0.23 | ||
| Q2 25 | — | $0.13 | ||
| Q1 25 | $-0.42 | $0.16 | ||
| Q4 24 | $-0.20 | $0.14 | ||
| Q3 24 | $-0.35 | $0.22 | ||
| Q2 24 | $1.55 | $0.25 | ||
| Q1 24 | $0.68 | $0.24 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $67.8M | $264.2M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $417.3M | $139.7M |
| Total Assets | $486.5M | $1.2B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $264.2M | ||
| Q3 25 | — | $211.1M | ||
| Q2 25 | — | $199.5M | ||
| Q1 25 | $67.8M | $198.4M | ||
| Q4 24 | $101.2M | $216.9M | ||
| Q3 24 | $78.0M | $216.8M | ||
| Q2 24 | $185.3M | $166.3M | ||
| Q1 24 | $68.4M | $168.6M |
| Q4 25 | — | $139.7M | ||
| Q3 25 | — | $137.4M | ||
| Q2 25 | — | $134.3M | ||
| Q1 25 | $417.3M | $132.9M | ||
| Q4 24 | $428.7M | $130.4M | ||
| Q3 24 | $422.4M | $132.9M | ||
| Q2 24 | $429.9M | $127.3M | ||
| Q1 24 | $269.4M | $124.2M |
| Q4 25 | — | $1.2B | ||
| Q3 25 | — | $1.2B | ||
| Q2 25 | — | $1.2B | ||
| Q1 25 | $486.5M | $1.2B | ||
| Q4 24 | $526.3M | $1.2B | ||
| Q3 24 | $554.6M | $1.3B | ||
| Q2 24 | $582.0M | $1.2B | ||
| Q1 24 | $510.8M | $1.2B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-38.5M | $22.1M |
| Free Cash FlowOCF − Capex | $-39.7M | $19.8M |
| FCF MarginFCF / Revenue | -192.9% | 146.0% |
| Capex IntensityCapex / Revenue | 5.6% | 16.8% |
| Cash ConversionOCF / Net Profit | — | 6.46× |
| TTM Free Cash FlowTrailing 4 quarters | $-58.0M | $36.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $22.1M | ||
| Q3 25 | — | $7.0M | ||
| Q2 25 | — | $8.7M | ||
| Q1 25 | $-38.5M | $3.0M | ||
| Q4 24 | $-31.6M | $19.6M | ||
| Q3 24 | $-24.3M | $5.4M | ||
| Q2 24 | $39.8M | $2.3M | ||
| Q1 24 | $-25.5M | $7.4M |
| Q4 25 | — | $19.8M | ||
| Q3 25 | — | $6.1M | ||
| Q2 25 | — | $8.1M | ||
| Q1 25 | $-39.7M | $2.9M | ||
| Q4 24 | $-32.2M | $18.6M | ||
| Q3 24 | $-24.9M | $5.3M | ||
| Q2 24 | $38.8M | $2.0M | ||
| Q1 24 | $-26.4M | $7.0M |
| Q4 25 | — | 146.0% | ||
| Q3 25 | — | 43.7% | ||
| Q2 25 | — | 64.3% | ||
| Q1 25 | -192.9% | 21.2% | ||
| Q4 24 | -86.2% | 156.0% | ||
| Q3 24 | -127.3% | 38.1% | ||
| Q2 24 | 41.0% | 15.5% | ||
| Q1 24 | -44.6% | 54.8% |
| Q4 25 | — | 16.8% | ||
| Q3 25 | — | 6.0% | ||
| Q2 25 | — | 4.6% | ||
| Q1 25 | 5.6% | 0.9% | ||
| Q4 24 | 1.7% | 8.7% | ||
| Q3 24 | 3.3% | 0.7% | ||
| Q2 24 | 1.1% | 2.2% | ||
| Q1 24 | 1.4% | 3.6% |
| Q4 25 | — | 6.46× | ||
| Q3 25 | — | 1.73× | ||
| Q2 25 | — | 4.01× | ||
| Q1 25 | — | 1.13× | ||
| Q4 24 | -27.94× | 7.87× | ||
| Q3 24 | — | 1.40× | ||
| Q2 24 | 0.72× | 0.54× | ||
| Q1 24 | -1.09× | 1.79× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
